{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T18:21:15Z","timestamp":1794507675578,"version":"4.9.1"},"reference-count":97,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,2,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>P2Y12, the Gi-coupled platelet receptor for adenosine diphosphate (ADP), plays a central role in platelet function. Patients with congenital P2Y12 defects display a mild to moderate bleeding diathesis, characterized by mucocutaneous bleedings and excessive post-surgical and post-traumatic blood loss. Defects of P2Y12 should be suspected when ADP, even at high concentrations (\u2265 10\u03bcM), is unable to induce full, irreversible platelet aggregation. Tests that evaluate the degree of inhibition of adenylyl cyclase by ADP should be used to confirm the diagnosis. Drugs that inhibit P2Y12 are potent antithrombotic drugs, attesting the central role played by P2Y12 in platelet thrombus formation. Clopidogrel, the most widely used drug that inhibits P2Y12, is effective both in monotherapy and in combination with acetylsalicylic acid. The most important drawback of clopidogrel is its inability to inhibit adequately P2Y12-dependent platelet function in approximately one-third of patients who are therefore not protected from major cardiovascular events. New drugs, such as prasugrel and ticagrelor, which effectively inhibit P2Y12 in the majority of patients, proved to be more efficacious than clopdidogrel in preventing major cardiovascular events. Although they increase the incidence of major bleedings, the net clinical benefit is in favor of the new P2Y12 inhibitors.<\/jats:p>","DOI":"10.1182\/blood-2010-08-263111","type":"journal-article","created":{"date-parts":[[2010,10,22]],"date-time":"2010-10-22T01:40:51Z","timestamp":1287711651000},"page":"2102-2112","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":170,"title":["The platelet P2Y12 receptor for adenosine diphosphate: congenital and drug-induced defects"],"prefix":"10.1182","volume":"117","author":[{"given":"Marco","family":"Cattaneo","sequence":"first","affiliation":[{"name":"Unit\u00e0 di Medicina 3, Ospedale San Paolo, Dipartimento di Medicina, Chirurgia e Odontoiatria, Universit\u00e0 degli Studi di Milano, Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"2","key":"2019111808100226400_B1","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1055\/s-2005-869518","article-title":"Platelet aggregation and adenosine diphosphate\/adenosine triphosphate receptors: a historical perspective.","volume":"31","author":"Packham","year":"2005","journal-title":"Semin Thromb Hemost"},{"issue":"10","key":"2019111808100226400_B2","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1161\/01.ATV.19.10.2281","article-title":"ADP receptors and clinical bleeding disorders.","volume":"19","author":"Cattaneo","year":"1999","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"5","key":"2019111808100226400_B3","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1182\/blood.V75.5.1081.1081","article-title":"Released adenosine diphosphate stabilizes thrombin-induced human platelet aggregates.","volume":"75","author":"Cattaneo","year":"1990","journal-title":"Blood"},{"issue":"1","key":"2019111808100226400_B4","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1055\/s-0038-1642389","article-title":"Ticlopidine facilitates the deaggregation of human platelets aggregated by thrombin.","volume":"71","author":"Cattaneo","year":"1994","journal-title":"Thromb Haemost"},{"issue":"12","key":"2019111808100226400_B5","doi-asserted-by":"crossref","first-page":"4156","DOI":"10.1182\/blood.V94.12.4156","article-title":"A key role of adenosine diphosphate in the irreversible platelet aggregation induced by the PAR1-activating peptide through the late activation of phosphoinositide 3-kinase.","volume":"94","author":"Trumel","year":"1999","journal-title":"Blood"},{"issue":"1","key":"2019111808100226400_B6","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.tips.2004.10.010","article-title":"The recently deorphanized GPR80 (GPR99) proposed to be the P2Y15 receptor is not a genuine P2Y receptor.","volume":"26","author":"Abbracchio","year":"2005","journal-title":"Trends Pharmacol Sci"},{"issue":"14","key":"2019111808100226400_B7","doi-asserted-by":"crossref","first-page":"8070","DOI":"10.1073\/pnas.95.14.8070","article-title":"Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation.","volume":"95","author":"Jin","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2019111808100226400_B8","first-page":"201","article-title":"The platelet P2 receptors.","volume-title":"Platelets","author":"Cattaneo","year":"2006"},{"issue":"29","key":"2019111808100226400_B9","doi-asserted-by":"crossref","first-page":"11069","DOI":"10.1073\/pnas.0510446103","article-title":"The active metabolite of Clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts.","volume":"103","author":"Savi","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"2019111808100226400_B10","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1055\/s-0037-1614133","article-title":"Identification and biological activity of the active metabolite of clopidogrel.","volume":"84","author":"Savi","year":"2000","journal-title":"Thromb Haemost"},{"issue":"10","key":"2019111808100226400_B11","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1182\/blood-2002-10-3027","article-title":"Inactivation of the human P2Y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, Cys17 and Cys270.","volume":"101","author":"Ding","year":"2003","journal-title":"Blood"},{"issue":"1","key":"2019111808100226400_B12","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0014-5793(04)00191-7","article-title":"N-linked glycosylation of platelet P2Y12 ADP receptor is essential for signal transduction but not for ligand binding or cell surface expression.","volume":"562","author":"Zhong","year":"2004","journal-title":"FEBS Lett"},{"issue":"11","key":"2019111808100226400_B13","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1111\/j.1538-7836.2004.00926.x","article-title":"Adenine triphosphate nucleotides are antagonists at the P2Y receptor.","volume":"2","author":"Kauffenstein","year":"2004","journal-title":"J Thromb Haemost"},{"issue":"5","key":"2019111808100226400_B14","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1111\/j.1538-7836.2005.01325.x","article-title":"Lipid rafts are required in Galpha(i) signaling downstream of the P2Y12 receptor during ADP-mediated platelet activation.","volume":"3","author":"Quinton","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"3","key":"2019111808100226400_B15","first-page":"333","article-title":"Interactions of the pharmacological receptors of blood platelets with adenylate cyclase.","volume":"6","author":"Haslam","year":"1973","journal-title":"Ser Haematol"},{"issue":"2","key":"2019111808100226400_B16","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/00001721-199603000-00035","article-title":"cAMP is not an important messenger for ADP-induced platelet aggregation.","volume":"7","author":"Savi","year":"1996","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"10","key":"2019111808100226400_B17","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1182\/blood.V96.10.3439","article-title":"FcgammaRIIA requires a Gi-dependent pathway for an efficient stimulation of phosphoinositide 3-kinase, calcium mobilization, and platelet aggregation.","volume":"96","author":"Gratacap","year":"2000","journal-title":"Blood"},{"issue":"2","key":"2019111808100226400_B18","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1055\/s-0037-1615690","article-title":"Potentiation of thromboxane A2-induced platelet secretion by Gi signaling through the phosphoinositide-3 kinase pathway.","volume":"85","author":"Dangelmaier","year":"2000","journal-title":"Thromb Haemost"},{"issue":"11","key":"2019111808100226400_B19","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1096\/fj.00-0810fje","article-title":"Resistance to thromboembolism in PI3Kgamma-deficient mice.","volume":"15","author":"Hirsch","year":"2001","journal-title":"FASEB J"},{"issue":"2","key":"2019111808100226400_B20","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1042\/bst0320387","article-title":"Phosphoinositide 3-kinases and the regulation of platelet function.","volume":"32","author":"Jackson","year":"2004","journal-title":"Biochem Soc Trans"},{"issue":"2","key":"2019111808100226400_B21","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1042\/BJ20100166","article-title":"Role of phosphoinositide 3-kinase beta in platelet aggregation and thromboxane A2 generation mediated by Gi signalling pathways.","volume":"429","author":"Garcia","year":"2010","journal-title":"Biochem J"},{"issue":"2","key":"2019111808100226400_B22","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/sj.bjp.0703046","article-title":"ADP can induce aggregation of human platelets via both P2Y(1) and P(2T) receptors.","volume":"129","author":"Jarvis","year":"2000","journal-title":"Br J Pharmacol"},{"issue":"2","key":"2019111808100226400_B23","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0014-5793(01)02824-1","article-title":"The P2Y(12) receptor induces platelet aggregation through weak activation of the alpha(IIb)beta(3) integrin: a phosphoinositide 3-kinase-dependent mechanism.","volume":"505","author":"Kauffenstein","year":"2001","journal-title":"FEBS Lett"},{"issue":"2","key":"2019111808100226400_B24","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1055\/s-2005-869522","article-title":"The P2 receptors and congenital platelet function defects.","volume":"31","author":"Cattaneo","year":"2005","journal-title":"Semin Thromb Hemost"},{"issue":"5","key":"2019111808100226400_B25","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1055\/s-0038-1656090","article-title":"Deficiency of [33P]2MeS-ADP binding sites on platelets with secretion defect, normal granule stores and normal thromboxane A2 production: evidence that ADP potentiates platelet secretion independently of the formation of large platelet aggregates and thromboxane A2 production.","volume":"77","author":"Cattaneo","year":"1997","journal-title":"Thromb Haemost"},{"issue":"11","key":"2019111808100226400_B26","doi-asserted-by":"crossref","first-page":"E101","DOI":"10.1161\/01.ATV.20.11.e101","article-title":"Platelets from a patient heterozygous for the defect of P2CYC receptors for ADP have a secretion defect despite normal thromboxane A2 production and normal granule stores: further evidence that some cases of platelet \u2018primary secretion defect\u2019 are heterozygous for a defect of P2CYC receptors.","volume":"20","author":"Cattaneo","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2019111808100226400_B27","first-page":"83","article-title":"ADP potentiates platelet-dense granule secretion induced by U46619 or TRAP through its interaction with the P2cyc receptor [abstract].","volume":"85","author":"Lecchi","year":"2000","journal-title":"Haematologica"},{"issue":"33","key":"2019111808100226400_B28","doi-asserted-by":"crossref","first-page":"30725","DOI":"10.1074\/jbc.M301838200","article-title":"Two waves of platelet secretion induced by thromboxane A2 receptor and a critical role for phosphoinositide 3-kinases.","volume":"278","author":"Li","year":"2003","journal-title":"J Biol Chem"},{"issue":"4","key":"2019111808100226400_B29","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1055\/s-0037-1615655","article-title":"Differential involvement of the P2Y1 and P2YT receptors in the morphological changes of platelet aggregation.","volume":"85","author":"Eckly","year":"2001","journal-title":"Thromb Haemost"},{"issue":"11","key":"2019111808100226400_B30","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1182\/blood.V80.11.2787.2787","article-title":"Identification of a new congenital defect of platelet function characterized by severe impairment of platelet responses to adenosine diphosphate.","volume":"80","author":"Cattaneo","year":"1992","journal-title":"Blood"},{"issue":"12","key":"2019111808100226400_B31","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1172\/JCI12242","article-title":"Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs.","volume":"107","author":"Foster","year":"2001","journal-title":"J Clin Invest"},{"issue":"4","key":"2019111808100226400_B32","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1073\/pnas.0437879100","article-title":"Molecular bases of defective signal transduction in the platelet P2Y12 receptor of a patient with congenital bleeding.","volume":"100","author":"Cattaneo","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"2019111808100226400_B33","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1172\/JCI17864","article-title":"P2Y12 regulates platelet adhesion\/activation, thrombus growth, and thrombus stability in injured arteries.","volume":"112","author":"Andre","year":"2003","journal-title":"J Clin Invest"},{"issue":"4","key":"2019111808100226400_B34","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1172\/JCI117835","article-title":"An inherited bleeding disorder linked to a defective interaction between ADP and its receptor on platelets: its influence on glycoprotein IIb-IIIa complex function.","volume":"95","author":"Nurden","year":"1995","journal-title":"J Clin Invest"},{"issue":"3","key":"2019111808100226400_B35","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1161\/01.ATV.13.3.393","article-title":"Shear-induced platelet aggregation is potentiated by desmopressin (DDAVP) and inhibited by ticlopidine.","volume":"13","author":"Cattaneo","year":"1993","journal-title":"Arterioscler Thromb"},{"issue":"4","key":"2019111808100226400_B36","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/j.1365-2141.1994.tb05123.x","article-title":"Role of ADP in platelet aggregation at high shear: studies in a patient with congenital defect of platelet responses to ADP.","volume":"88","author":"Cattaneo","year":"1994","journal-title":"Br J Haematol"},{"issue":"3","key":"2019111808100226400_B37","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1124\/mol.63.3.639","article-title":"Purinergic P2Y12 receptor blockade inhibits shear-induced platelet phosphatidylinositol 3-kinase activation.","volume":"63","author":"Resendiz","year":"2003","journal-title":"Mol Pharmacol"},{"issue":"3","key":"2019111808100226400_B38","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/j.1538-7836.2007.02356.x","article-title":"Inhibition of the platelet P2Y12 receptor for adenosine diphosphate potentiates the antiplatelet effect of prostacyclin.","volume":"5","author":"Cattaneo","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"2","key":"2019111808100226400_B39","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/j.1365-2141.1995.tb05319.x","article-title":"Purinoceptors on blood platelets: further pharmacological and clinical evidence to suggest the presence of two ADP receptors.","volume":"91","author":"Gachet","year":"1995","journal-title":"Br J Haematol"},{"issue":"10","key":"2019111808100226400_B40","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1111\/j.1538-7836.2005.01554.x","article-title":"Impaired platelet function in a patients with P2Y12 deficiency caused by a mutation in the translation initiation codon.","volume":"3","author":"Shiraga","year":"2005","journal-title":"J Thromb Haemost"},{"key":"2019111808100226400_B41","article-title":"Identification of a novel homozygous P2Y12 mutation in a patient with a mild platelet-based bleeding disorder [abstract].","volume":"7","author":"Dawood","year":"2009","journal-title":"J Thromb Haemost"},{"issue":"7","key":"2019111808100226400_B42","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1046\/j.1538-7836.2003.00266.x","article-title":"Inherited platelet-based bleeding disorders.","volume":"1","author":"Cattaneo","year":"2003","journal-title":"J Thromb Haemost"},{"key":"2019111808100226400_B43","first-page":"43","article-title":"Unique mutations in the P2Y12 locus of patients with previously described defects in ADP-dependent aggregation [abstract].","volume":"98","author":"Conley","year":"2001","journal-title":"Blood"},{"issue":"4","key":"2019111808100226400_B44","doi-asserted-by":"crossref","first-page":"581","DOI":"10.3324\/haematol.13611","article-title":"Haploinsufficiency of the platelet P2Y12 gene in a family with congenital bleeding diathesis.","volume":"94","author":"Fontana","year":"2009","journal-title":"Haematologica"},{"issue":"6817","key":"2019111808100226400_B45","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/35051599","article-title":"Identification of the platelet ADP receptor targeted by antithrombotic drugs.","volume":"409","author":"Hollopeter","year":"2001","journal-title":"Nature"},{"issue":"12","key":"2019111808100226400_B46","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1021\/bi982369v","article-title":"Role of the extracellular loops of G protein-coupled receptors in ligand recognition: a molecular modeling study of the human P2Y1 receptor.","volume":"38","author":"Moro","year":"1999","journal-title":"Biochemistry"},{"issue":"9","key":"2019111808100226400_B47","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1021\/jm970684u","article-title":"Human P2Y1 receptor: molecular modeling and site-directed mutagenesis as tools to identify agonist and antagonist recognition sites.","volume":"41","author":"Moro","year":"1998","journal-title":"J Med Chem"},{"issue":"2","key":"2019111808100226400_B48","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1515\/CCLM.2007.036","article-title":"Novel molecular defect in the platelet ADP receptor P2Y12 of a patient with haemorrhagic diathesis.","volume":"45","author":"Remijn","year":"2007","journal-title":"Clin Chem Lab Med"},{"issue":"17","key":"2019111808100226400_B49","doi-asserted-by":"crossref","first-page":"4110","DOI":"10.1182\/blood-2008-11-190850","article-title":"Identification and characterization of a novel P2Y 12 variant in a patient diagnosed with type 1 von Willebrand disease in the European MCMDM-1VWD study.","volume":"113","author":"Daly","year":"2009","journal-title":"Blood"},{"issue":"4","key":"2019111808100226400_B50","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/j.1538-7836.2006.01847.x","article-title":"A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD).","volume":"4","author":"Tosetto","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"10","key":"2019111808100226400_B51","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1111\/j.1538-7836.2010.04002.x","article-title":"Usefulness of a flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of patients with genetic defects of the platelet P2Y12 receptor for ADP.","volume":"8","author":"Zighetti","year":"2010","journal-title":"J Thromb Haemost"},{"key":"2019111808100226400_B52","first-page":"855","article-title":"Desmopressin.","volume-title":"Platelets","author":"Cattaneo","year":"2002"},{"key":"2019111808100226400_B53","first-page":"1127","article-title":"ADP receptors antagonists.","volume-title":"Platelets","author":"Cattaneo","year":"2006"},{"issue":"1","key":"2019111808100226400_B54","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1161\/CIRCULATIONAHA.109.853069","article-title":"New P2Y(12) inhibitors.","volume":"121","author":"Cattaneo","year":"2010","journal-title":"Circulation"},{"issue":"8649","key":"2019111808100226400_B55","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/S0140-6736(89)92327-1","article-title":"The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke.","volume":"1","author":"Gent","year":"1989","journal-title":"Lancet"},{"issue":"8","key":"2019111808100226400_B56","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJM198908243210804","article-title":"A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients: Ticlopidine Aspirin Stroke Study Group.","volume":"321","author":"Hass","year":"1989","journal-title":"N Engl J Med"},{"issue":"17","key":"2019111808100226400_B57","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1056\/NEJM199604253341702","article-title":"A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents.","volume":"334","author":"Sch\u00f6mig","year":"1996","journal-title":"N Engl J Med"},{"issue":"23","key":"2019111808100226400_B58","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1056\/NEJM199812033392303","article-title":"A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting.","volume":"339","author":"Leon","year":"1998","journal-title":"N Engl J Med"},{"issue":"9038","key":"2019111808100226400_B59","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE).","volume":"348","author":"CAPRIE Steering Committee","year":"1996","journal-title":"Lancet"},{"issue":"16","key":"2019111808100226400_B60","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa060989","article-title":"Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.","volume":"354","author":"Bhatt","year":"2006","journal-title":"N Engl J Med"},{"issue":"9431","key":"2019111808100226400_B61","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(04)16721-4","article-title":"Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial.","volume":"364","author":"Diener","year":"2004","journal-title":"Lancet"},{"issue":"7","key":"2019111808100226400_B62","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.","volume":"345","author":"Yusuf","year":"2001","journal-title":"N Engl J Med"},{"issue":"9497","key":"2019111808100226400_B63","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/S0140-6736(05)67660-X","article-title":"Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial.","volume":"366","author":"Chen","year":"2005","journal-title":"Lancet"},{"issue":"9281","key":"2019111808100226400_B64","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(01)05701-4","article-title":"Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.","volume":"358","author":"Mehta","year":"2001","journal-title":"Lancet"},{"issue":"2","key":"2019111808100226400_B65","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ahj.2007.04.014","article-title":"Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis.","volume":"154","author":"Snoep","year":"2007","journal-title":"Am Heart J"},{"issue":"7","key":"2019111808100226400_B66","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1182\/blood-2006-04-013052","article-title":"Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects.","volume":"108","author":"Hulot","year":"2006","journal-title":"Blood"},{"issue":"12","key":"2019111808100226400_B67","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1111\/j.1538-7836.2007.02775.x","article-title":"Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel.","volume":"5","author":"Brandt","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"2","key":"2019111808100226400_B68","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jacc.2009.12.071","article-title":"Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis.","volume":"56","author":"Hulot","year":"2010","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"2019111808100226400_B69","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1056\/NEJMoa0808227","article-title":"Genetic determinants of response to clopidogrel and cardiovascular events.","volume":"360","author":"Simon","year":"2009","journal-title":"N Engl J Med"},{"issue":"9749","key":"2019111808100226400_B70","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/S0140-6736(10)61273-1","article-title":"Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis.","volume":"376","author":"Mega","year":"2010","journal-title":"Lancet"},{"issue":"8","key":"2019111808100226400_B71","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1001\/jama.2010.181","article-title":"Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation.","volume":"303","author":"Breet","year":"2010","journal-title":"JAMA"},{"issue":"1","key":"2019111808100226400_B72","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.acvd.2009.11.004","article-title":"Clopidogrel response: head-to-head comparison of different platelet assays to identify clopidogrel non responder patients after coronary stenting.","volume":"103","author":"Cuisset","year":"2010","journal-title":"Arch Cardiovasc Dis"},{"issue":"2","key":"2019111808100226400_B73","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1160\/TH08-09-0577","article-title":"Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation.","volume":"101","author":"Gremmel","year":"2009","journal-title":"Thromb Haemost"},{"issue":"2","key":"2019111808100226400_B74","first-page":"287","article-title":"Comparison of methods for monitoring residual platelet reactivity after clopidogrel by point-of-care tests on whole blood in high-risk patients.","volume":"104","author":"Paniccia","year":"2010","journal-title":"Thromb Haemost"},{"issue":"4","key":"2019111808100226400_B75","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/s11239-010-0484-2","article-title":"Correlation of high post-treatment platelet reactivity assessed by light transmittance aggregometry and the VerifyNow P2Y(12) assay.","volume":"30","author":"Kim","year":"2010","journal-title":"J Thromb Thrombolysis"},{"issue":"5","key":"2019111808100226400_B76","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1373\/clinchem.2009.137471","article-title":"Long-term aspirin and clopidogrel response evaluated by light transmission aggregometry, VerifyNow, and thrombelastography in patients undergoing percutaneous coronary intervention.","volume":"56","author":"Madsen","year":"2010","journal-title":"Clin Chem"},{"issue":"10","key":"2019111808100226400_B77","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1111\/j.1538-7836.2009.03554.x","article-title":"CYP2C19*2 polymorphism is not the sole determinant of the response to clopidogrel: implications for its monitoring.","volume":"7","author":"Aleil","year":"2009","journal-title":"J Thromb Haemost"},{"issue":"22","key":"2019111808100226400_B78","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1016\/j.jacc.2010.02.031","article-title":"Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement.","volume":"55","author":"Hochholzer","year":"2010","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"2019111808100226400_B79","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.amjcard.2008.08.048","article-title":"Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis.","volume":"103","author":"Bonello","year":"2009","journal-title":"Am J Cardiol"},{"issue":"21","key":"2019111808100226400_B80","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1161\/CIRCULATIONAHA.108.857722","article-title":"Can we override clopidogrel resistance?","volume":"119","author":"Pena","year":"2009","journal-title":"Circulation"},{"issue":"12","key":"2019111808100226400_B81","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.jacc.2010.04.047","article-title":"Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate.","volume":"56","author":"Bonello","year":"2010","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"2019111808100226400_B82","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes.","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"issue":"1","key":"2019111808100226400_B83","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/eurheartj\/ehm545","article-title":"Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease.","volume":"29","author":"Wallentin","year":"2008","journal-title":"Eur Heart J"},{"issue":"7","key":"2019111808100226400_B84","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1111\/j.1538-7836.2007.02598.x","article-title":"The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite.","volume":"5","author":"Sugidachi","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"2","key":"2019111808100226400_B85","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1055\/s-2005-869525","article-title":"Preclinical and clinical studies with selective reversible direct P2Y12 antagonists.","volume":"31","author":"van Giezen","year":"2005","journal-title":"Semin Thromb Hemost"},{"issue":"5","key":"2019111808100226400_B86","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00228-009-0778-5","article-title":"Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y(12) receptor antagonist, in healthy subjects.","volume":"66","author":"Teng","year":"2010","journal-title":"Eur J Clin Pharmacol"},{"issue":"9","key":"2019111808100226400_B87","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1111\/j.1538-7836.2009.03527.x","article-title":"Ticagrelor binds to the human P2Y receptor independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation.","volume":"7","author":"van Giezen","year":"2009","journal-title":"J Thromb Haemost"},{"issue":"9","key":"2019111808100226400_B88","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/eurheartj\/ehi754","article-title":"Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin.","volume":"27","author":"Husted","year":"2006","journal-title":"Eur Heart J"},{"issue":"19","key":"2019111808100226400_B89","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1016\/j.jacc.2007.07.053","article-title":"Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial.","volume":"50","author":"Cannon","year":"2007","journal-title":"J Am Coll Cardiol"},{"issue":"25","key":"2019111808100226400_B90","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1161\/CIRCULATIONAHA.109.912550","article-title":"Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET\/OFFSET study.","volume":"120","author":"Gurbel","year":"2009","journal-title":"Circulation"},{"issue":"11","key":"2019111808100226400_B91","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes.","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"issue":"24","key":"2019111808100226400_B92","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1056\/NEJMoa0908629","article-title":"Intravenous platelet blockade with cangrelor during PCI.","volume":"361","author":"Bhatt","year":"2009","journal-title":"N Engl J Med"},{"issue":"24","key":"2019111808100226400_B93","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1056\/NEJMoa0908628","article-title":"Platelet inhibition with cangrelor in patients undergoing PCI.","volume":"361","author":"Harrington","year":"2009","journal-title":"N Engl J Med"},{"issue":"23","key":"2019111808100226400_B94","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1016\/j.jacc.2009.09.076","article-title":"A risk score to predict bleeding in patients with acute coronary syndromes.","volume":"55","author":"Mehran","year":"2010","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"2019111808100226400_B95","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1161\/CIRCULATIONAHA.106.612812","article-title":"Adverse impact of bleeding on prognosis in patients with acute coronary syndromes.","volume":"114","author":"Eikelboom","year":"2006","journal-title":"Circulation"},{"issue":"1","key":"2019111808100226400_B96","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1161\/CIRCULATIONAHA.109.878017","article-title":"Prognostic modeling of individual patient risk and mortality impact of ischemic and hemorrhagic complications: assessment from the Acute Catheterization and Urgent Intervention Triage Strategy trial.","volume":"121","author":"Pocock","year":"2010","journal-title":"Circulation"},{"issue":"16","key":"2019111808100226400_B97","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1161\/CIRCULATIONAHA.109.858365","article-title":"Bleeding increases the risk of ischemic events in patients with peripheral arterial disease.","volume":"120","author":"van Hattum","year":"2009","journal-title":"Circulation"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/117\/7\/2102\/1492193\/zh800711002102.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/117\/7\/2102\/1492193\/zh800711002102.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T08:30:46Z","timestamp":1574065846000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/117\/7\/2102\/28211\/The-platelet-P2Y12-receptor-for-adenosine"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2,17]]},"references-count":97,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2011,2,17]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2010-08-263111","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,2,17]]}}}